>
Achilles Therapeutics logo

ACHL - Achilles Therapeutics Share Price

$15.15 0.6  3.8%

Last Trade - 16/04/21

Market Cap £648.0m
Enterprise Value £519.4m
Revenue £n/a
Position in Universe 2926th / 6850
Bullish
Bearish
Unlock ACHL Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -20.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AchillesTherapeutics PLC (ADR) revenues was not reported. Net lossincreased from $14M to $33.2M. Higher net loss reflectsResearch and development increase from $8.7M to $21.3M(expense), General and administrative increase from $4.3Mto $9.4M (expense), Stock-based Compensation in SGAincrease from $387K to $1.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ACHL Revenue Unlock ACHL Revenue

Net Income

ACHL Net Income Unlock ACHL Revenue

Normalised EPS

ACHL Normalised EPS Unlock ACHL Revenue

PE Ratio Range

ACHL PE Ratio Range Unlock ACHL Revenue

Dividend Yield Range

ACHL Dividend Yield Range Unlock ACHL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ACHL EPS Forecasts Unlock ACHL Revenue
Profile Summary

Achilles Therapeutics plc is a clinical stage immuno-oncology biopharmaceutical company that is engaged in developing precision T cell therapies to treat multiple types of solid tumors. The Company has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The Company's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated November 18, 2020
Public Since March 31, 2021
No. of Shareholders: n/a
No. of Employees: 153
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 59,150,955
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ACHL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ACHL
Upcoming Events for ACHL
Frequently Asked Questions for Achilles Therapeutics
What is the Achilles Therapeutics share price?

As of 16/04/21, shares in Achilles Therapeutics are trading at $15.15, giving the company a market capitalisation of £648.0m. This share price information is delayed by 15 minutes.

How has the Achilles Therapeutics share price performed this year?

Shares in Achilles Therapeutics are currently trading at $15.15 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Achilles Therapeutics price has moved by % over the past year.

What are the analyst and broker recommendations for Achilles Therapeutics?

There are no analysts currently covering Achilles Therapeutics.

When will Achilles Therapeutics next release its financial results?

Achilles Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Achilles Therapeutics dividend yield?

Achilles Therapeutics does not currently pay a dividend.

Does Achilles Therapeutics pay a dividend?

Achilles Therapeutics does not currently pay a dividend.

When does Achilles Therapeutics next pay dividends?

Achilles Therapeutics does not currently pay a dividend.

How do I buy Achilles Therapeutics shares?

To buy shares in Achilles Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Achilles Therapeutics?

Shares in Achilles Therapeutics are currently trading at $15.15, giving the company a market capitalisation of £648.0m.

Where are Achilles Therapeutics shares listed? Where are Achilles Therapeutics shares listed?

Here are the trading details for Achilles Therapeutics:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ACHL
What kind of share is Achilles Therapeutics?

Based on an overall assessment of its quality, value and momentum, Achilles Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Achilles Therapeutics share price forecast 2021?

We were not able to load any forecast data for Achilles Therapeutics.

How can I tell whether the Achilles Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Achilles Therapeutics. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $15.15, shares in Achilles Therapeutics are trading at 1.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Achilles Therapeutics PE Ratio?

We were not able to find PE ratio data for Achilles Therapeutics.

Who are the key directors of Achilles Therapeutics?

We were unable to find the directors for Achilles Therapeutics.

Who are the major shareholders of Achilles Therapeutics?

Here are the top five shareholders of Achilles Therapeutics based on the size of their shareholding:

Similar to ACHL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.